Greenhouse gas emissions associated with severe asthma care in the United Kingdom.

Alex Wilkinson, Mina Khezrian, Liam G Heaney, Soram Patel, Jennifer K Quint, Hitasha Rupani, Eleni Rapsomaniki, Kirsty Rhodes, Andrew N Menzies-Gow, Trung N Tran
{"title":"Greenhouse gas emissions associated with severe asthma care in the United Kingdom.","authors":"Alex Wilkinson, Mina Khezrian, Liam G Heaney, Soram Patel, Jennifer K Quint, Hitasha Rupani, Eleni Rapsomaniki, Kirsty Rhodes, Andrew N Menzies-Gow, Trung N Tran","doi":"10.1016/j.jaip.2025.02.012","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The COP28 Declaration on Climate and Health promotes steps to curb emissions and reduce waste in the health sector.</p><p><strong>Objective: </strong>To describe and quantify greenhouse gas (GHG) emissions associated with severe asthma (SA) care in the UK, by carbon source and transition status from SA to severe uncontrolled asthma (SUA) and/or regular specialist care (RSC).</p><p><strong>Methods: </strong>This was a cohort study using routinely collected data from the Clinical Practice Research Datalink Aurum, Hospital Episode Statistics and CO<sub>2</sub> equivalent emissions data. Patients were ≥12 years old at index date (i.e. date of first recorded ICS + controller prescription) with a validated asthma diagnosis. Total-, medication-, exacerbation- and healthcare resource utilisation (HCRU)-related GHG emissions were estimated, overall and by transition along stages of the SA-SUA-RSC continuum. Five pathways and stage orders were identified: 1. SA, 2. SA-SUA, 3. SA-RSC, 4. SA-RSC-SUA, 5. SA-SUA-RSC.</p><p><strong>Results: </strong>Total CO<sub>2</sub> eq for the SA population (n=93,054) was 2167 tonnes/10K patients/year. GHG emissions were 5.2-23.0% greater for patients transitioned to SUA (versus previous stage), mostly due to exacerbation-related emissions (4.2-7.7 times greater; predominantly hospitalizations) and medication-related emissions (3.5-10.9% greater; predominantly SABAs). Conversely, total GHG emissions decreased by 12.1-23.9% for those referred to RSC, due to decreased exacerbation-related emissions (1.7-5.2 times lower; all sources) and medication-related emissions (14.8-20.6% lower; both SABA and overall ICS).</p><p><strong>Conclusion: </strong>Our findings suggest that RSC not only improves patient outcomes but also reduces GHG emissions in line with aims to reduce the health sector's contribution to the total national carbon footprint.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaip.2025.02.012","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The COP28 Declaration on Climate and Health promotes steps to curb emissions and reduce waste in the health sector.

Objective: To describe and quantify greenhouse gas (GHG) emissions associated with severe asthma (SA) care in the UK, by carbon source and transition status from SA to severe uncontrolled asthma (SUA) and/or regular specialist care (RSC).

Methods: This was a cohort study using routinely collected data from the Clinical Practice Research Datalink Aurum, Hospital Episode Statistics and CO2 equivalent emissions data. Patients were ≥12 years old at index date (i.e. date of first recorded ICS + controller prescription) with a validated asthma diagnosis. Total-, medication-, exacerbation- and healthcare resource utilisation (HCRU)-related GHG emissions were estimated, overall and by transition along stages of the SA-SUA-RSC continuum. Five pathways and stage orders were identified: 1. SA, 2. SA-SUA, 3. SA-RSC, 4. SA-RSC-SUA, 5. SA-SUA-RSC.

Results: Total CO2 eq for the SA population (n=93,054) was 2167 tonnes/10K patients/year. GHG emissions were 5.2-23.0% greater for patients transitioned to SUA (versus previous stage), mostly due to exacerbation-related emissions (4.2-7.7 times greater; predominantly hospitalizations) and medication-related emissions (3.5-10.9% greater; predominantly SABAs). Conversely, total GHG emissions decreased by 12.1-23.9% for those referred to RSC, due to decreased exacerbation-related emissions (1.7-5.2 times lower; all sources) and medication-related emissions (14.8-20.6% lower; both SABA and overall ICS).

Conclusion: Our findings suggest that RSC not only improves patient outcomes but also reduces GHG emissions in line with aims to reduce the health sector's contribution to the total national carbon footprint.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.10
自引率
9.60%
发文量
683
审稿时长
50 days
期刊介绍: JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases. This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders. The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.
期刊最新文献
Labeling barriers to delabeling penicillin allergy: an intersectional case study of gender identity, race, and syphilis. Exploring the Barriers and Benefits of Stock Inhaler Programs in Urban School Settings: Perspectives of Chicago School Nurses and Administrators. Social determinants and quality of life in food allergy management and treatment. Cover 1 Table of Contents
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1